# Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors

> **NCT03065062** · PHASE1 · SUSPENDED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 75 (estimated)

## Conditions studied

- Lung Cancer Squamous Cell
- Solid Tumors
- Head & Neck Cancer
- Pancreatic Cancer

## Interventions

- **DRUG:** Palbociclib
- **DRUG:** Gedatolisib

## Key facts

- **NCT ID:** NCT03065062
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2017-02-28
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-01-31
- **Target enrollment:** 75 (ESTIMATED)
- **Why stopped:** Funding and drug supply to continue the study are pending.
- **Last updated:** 2026-02-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03065062

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03065062, "Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03065062. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*